Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by 1Lighthouseon May 03, 2019 10:19am
113 Views
Post# 29706113

New B warrants make A warrants useless?

New B warrants make A warrants useless?I hate when companies do this, been through it once before. Why release new warrants that have lower exercise price and longer expiration than the previous warrants? Makes the original warrants essentially worthless, as who would buy them when the B warrants last longer and convert cheaper? Good thing I have 200,000 of the original worthless ones now lol, plus the same amount of newer ones at least.

But what’s up with that, why destroy the worth of original warrants? Couldn’t they have at the very least, put the newer exercise price half a cent above the old warrants, leaving some value to the original warrants?

Is this a sign of a scam company that isn’t actually interested in making progress, only raising money for hefty paycheques? I’m a believer in their products, but getting less excited about their success with every passing day, and after bad dealings.

Can someone shed some light please? Thanks
Bullboard Posts